Tagged with Strategy

Ireland James Lennertz, Group VP and GM EUMEA for BioMarin, discusses the key highlights of the past few years for BioMarin, their unique positioning as a company offering innovative therapies for ultra-rare diseases, the main challenge he sees for BioMarin’s international operations, and his priorities for the next few years. James,…

London Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing on a few key therapeutic areas, compared to a more diversified approach. If the 1990s and early 2000s, were all…

France Shedding light on the unique business model of French pharma’s most successful mid-cap.   Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but nonetheless formidably successful, Servier has, for…

Slovakia Pharma companies in Slovakia are managing to circumvent the problems inherent in the size of the local market by focusing on the country’s advantages in market access and regional leadership, as well as through joining together with affiliates in neighboring Czech Republic. “Slovakia is a developed and established EUR 1.25…

Ireland Deirdre Bourke, Country Lead at Eli Lilly’s Irish affiliate, highlights the strategic importance of Ireland to Lilly’s global operations, their exciting upcoming pipeline, the challenges and opportunities she foresees for Lilly in Ireland, and her own professional transition from managing Lilly’s diabetes portfolio to Lilly’s overall commercial activities in Ireland.…

Switzerland With 40 years of history in Switzerland, B Braun serves every hospital in the country and operates three distinct production sites. CEO Madeleine Stöckli discusses her strategy for improving productivity and finding opportunities for growth. Could you please briefly introduce yourself and B Braun Switzerland to our readers? B Braun…

Singapore Recently appointed Senior Vice President of Asia Pacific, Massimiliano Colella speaks about Smith & Nephew’s reasons for establishing a presence in the region, their dual approach in catering to the diversity of Southeast Asian markets, as well as the opportunities for growth in the region. Can you please provide some…

Ireland Iwer Baecker, MD of Bayer Ireland, outlines the Irish affiliate’s impressive growth in the past few years, the strategy of New Bayer and how it comes into play in Ireland, as well as how Ireland’s small size is not a constraint but rather a huge opportunity to be taken advantage…

Actelion Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20 billion. As Actelion is a market leader in some therapeutic areas such as pulmonary arterial hypertension (PAH), the acquisition could…

Philippines Alvin So, Bayer Consumer Health Country Division Head, discusses Bayer’s commitment in Consumer Health in the Philippines. He also discusses his vision for the future, including expanding the product portfolio in the country and continuing to be the partner of choice for the Filipino population. When you assumed the position…

Singapore In an exclusive interview with Richard Saynor at GSK, he outlines the growth of the CEP portfolio in emerging markets and highlights the opportunities and challenges in the region, as well as the strategic benefits of operating in Singapore.   Even though our key medicines have many generic competitors, their…

Mexico Jorge Romero Castañeda and María Eugenia Mendez, Healthcare & Life Science leader and Strategy & Operations Director at Deloitte respectively, share their expertise about the Healthcare & Life Science sector in Mexico and showcase the integral solutions that the firm offers to the industry to help companies gain competitiveness as…